SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune ...

Even the CEOs of Big Pharmas have come under fire. Activist investor Starboard Value has made no secret of its criticism of Pfizer CEO Albert Bourla’s track record, while GSK CEO Emma Walmsley fought ...

Find the latest Alumis Inc. (ALMS) stock quote, history, news and other vital information to help you with your stock trading and investing.

Alumis Inc. OverviewBiotechnology / Healthcare Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. It ...

Nasdaq Listed Alerts Market: After-Hours Alumis Inc. Common Stock (ALMS) Bid: $3.29 X 76 Ask: $3.35 X 870 Volume: 741,005 ...

A high-level overview of Artiva Biotherapeutics, Inc. (ARTV) stock. View (ARTV) real-time stock price, chart, news, analysis, analyst reviews and more.

AXTA | Complete Axalta Coating Systems Ltd. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.